- Home
- PETS vs QNTM Comparison
PETS vs QNTM Comparison
Compare PETS & QNTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETS
- QNTM
- Stock Information
- Founded
- PETS 1996
- QNTM 1998
- Country
- PETS United States
- QNTM Canada
- Employees
- PETS N/A
- QNTM N/A
- Industry
- PETS Retail-Drug Stores and Proprietary Stores
- QNTM
- Sector
- PETS Consumer Staples
- QNTM
- Exchange
- PETS Nasdaq
- QNTM NYSE
- Market Cap
- PETS 68.6M
- QNTM 69.3M
- IPO Year
- PETS N/A
- QNTM N/A
- Fundamental
- Price
- PETS $3.32
- QNTM $18.56
- Analyst Decision
- PETS Sell
- QNTM
- Analyst Count
- PETS 2
- QNTM 0
- Target Price
- PETS $3.35
- QNTM N/A
- AVG Volume (30 Days)
- PETS 127.9K
- QNTM 408.5K
- Earning Date
- PETS 08-05-2025
- QNTM 08-13-2025
- Dividend Yield
- PETS N/A
- QNTM N/A
- EPS Growth
- PETS N/A
- QNTM N/A
- EPS
- PETS 0.02
- QNTM N/A
- Revenue
- PETS $247,010,000.00
- QNTM N/A
- Revenue This Year
- PETS N/A
- QNTM N/A
- Revenue Next Year
- PETS N/A
- QNTM N/A
- P/E Ratio
- PETS $194.56
- QNTM N/A
- Revenue Growth
- PETS N/A
- QNTM N/A
- 52 Week Low
- PETS $2.90
- QNTM $2.70
- 52 Week High
- PETS $6.85
- QNTM $38.25
- Technical
- Relative Strength Index (RSI)
- PETS 42.37
- QNTM 50.64
- Support Level
- PETS $3.32
- QNTM $15.88
- Resistance Level
- PETS $3.49
- QNTM $24.32
- Average True Range (ATR)
- PETS 0.15
- QNTM 3.58
- MACD
- PETS 0.01
- QNTM -1.07
- Stochastic Oscillator
- PETS 51.35
- QNTM 13.59
About PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About QNTM QUANTUM BIOPHARMA LTD
Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property.